Cita APA (7a ed.)
Chayab, L., Leighl, N. B., Tadrous, M., Warren, C. M., & Wong, W. W. L. (2025). Trends in Real-World Clinical Outcomes of Patients with Anaplastic Lymphoma Kinase (ALK) Rearranged Non-Small Cell Lung Cancer (NSCLC) Receiving One or More ALK Tyrosine Kinase Inhibitors (TKIs): A Cohort Study in Ontario, Canada. Current Oncology, 32(1), 13-40.
Cita Chicago Style (17a ed.)
Chayab, Lara, Natasha B. Leighl, Mina Tadrous, Christine M. Warren, y William W. L. Wong. "Trends in Real-World Clinical Outcomes of Patients with Anaplastic Lymphoma Kinase (ALK) Rearranged Non-Small Cell Lung Cancer (NSCLC) Receiving One or More ALK Tyrosine Kinase Inhibitors (TKIs): A Cohort Study in Ontario, Canada." Current Oncology 32, no. 1 (2025): 13-40.
Cita MLA (9a ed.)
Chayab, Lara, et al. "Trends in Real-World Clinical Outcomes of Patients with Anaplastic Lymphoma Kinase (ALK) Rearranged Non-Small Cell Lung Cancer (NSCLC) Receiving One or More ALK Tyrosine Kinase Inhibitors (TKIs): A Cohort Study in Ontario, Canada." Current Oncology, vol. 32, no. 1, 2025, pp. 13-40.
Precaución: Estas citas no son 100% exactas.